Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trustworthy artificial intelligence in predictive medicine: cancer survival analysis using ethical-by-design and explainable artificial intelligence models.

JAMIA open·2026
Same author

Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcoma.

Science advances·2026
Same author

Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Advancing Preclinical Biology for Ewing Sarcoma: An International Effort.

Molecular cancer therapeutics·2025
Same author

Expanding the Spectrum of SRF-Rearranged Myoid Tumors: An Adult Case With SRF::SOHLH1 Fusion and Suspected Metastasis.

Genes, chromosomes & cancer·2025
Same author

Advancing Preclinical Biology for Ewing Sarcoma: An International Effort.

Molecular cancer therapeutics·2025
Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: Sep 2, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.8K

A Druggable Rheostat for Ewing Sarcoma?

Kurt R Weiss1, Kelly M Bailey2

  • 1Department of Orthopedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|August 3, 2022
PubMed
Summary
This summary is machine-generated.

Ewing sarcoma cells rely on the EWSR1::FLI1 fusion protein and HOXD13 expression to maintain a mesenchymal state. Targeting these master regulators is crucial for developing new Ewing sarcoma therapies.

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.5K
Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity
08:28

Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity

Published on: August 25, 2019

13.7K

Related Experiment Videos

Last Updated: Sep 2, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.8K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.5K
Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity
08:28

Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity

Published on: August 25, 2019

13.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ewing sarcoma is an aggressive bone and soft tissue cancer.
  • The EWSR1::FLI1 fusion oncogene drives tumor development.
  • HOXD13 expression is implicated in maintaining a mesenchymal cell state.

Purpose of the Study:

  • To investigate the regulatory relationship between EWSR1::FLI1 and HOXD13 in Ewing sarcoma.
  • To understand the role of HOXD13 in Ewing sarcoma cell plasticity.
  • To identify potential therapeutic targets within the EWSR1::FLI1/HOXD13 axis.

Main Methods:

  • Analysis of the posterior HOXD enhancer's function.
  • Assessment of HOXD13 expression levels.
  • Investigation of transcriptional programs regulated by EWSR1::FLI1 and HOXD13.

Main Results:

  • The posterior HOXD enhancer is a key regulator of HOXD13 expression, dependent on EWSR1::FLI1.
  • HOXD13 expression promotes a mesenchymal cell phenotype in Ewing sarcoma.
  • EWSR1::FLI1 and HOXD13 act antagonistically to control Ewing cell plasticity.

Conclusions:

  • EWSR1::FLI1 and HOXD13 are master regulators of Ewing sarcoma cell plasticity.
  • Targeting Ewing sarcoma cells in their mesenchymal states is a promising therapeutic strategy.